RPS6 and non-small cell lung carcinoma: The positivity of RPS6 and p-RPS6 (S235/236) is significantly higher in NSCLC clinical samples than in normal tissues (82.4% vs. 55.8% and 62.6% vs. 53.3%, respectively) [37].